Oncology Drug Crash Course: Elacestrant (Orserdu)
Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer
Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512